Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Geode Capital Management LLC lifted its position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 41.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 226,083 shares of the company’s stock after buying an additional 66,712 shares during the period. Geode Capital Management LLC’s holdings in Vigil Neuroscience were worth $769,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in VIGL. Acadian Asset Management LLC bought a new position in Vigil Neuroscience in the 2nd quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vigil Neuroscience during the 2nd quarter valued at about $87,000. Renaissance Technologies LLC grew its holdings in shares of Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares in the last quarter. Walleye Capital LLC increased its position in shares of Vigil Neuroscience by 334.4% in the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in Vigil Neuroscience in the third quarter valued at approximately $442,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Stock Performance

Shares of VIGL opened at $1.79 on Friday. Vigil Neuroscience, Inc. has a fifty-two week low of $1.49 and a fifty-two week high of $6.06. The firm has a 50 day moving average price of $2.40 and a 200-day moving average price of $3.25. The firm has a market cap of $73.17 million, a price-to-earnings ratio of -0.87 and a beta of 1.76.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on VIGL shares. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a research note on Friday, November 8th. Wedbush upped their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. William Blair assumed coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $19.75.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.